Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05526001Phase 3Active Not Recruiting

Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee Osteoarthritis

Role: lead

NCT02933827Phase 1Completed

Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease

Role: lead

NCT02784964Phase 1Completed

Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis

Role: lead

All 3 trials loaded